復宏漢霖(02696.HK)治療實體瘤藥物聯合化療3期臨牀研究達到主要研究終點
復宏漢霖(02696.HK)公佈,近日公司自主開發的斯魯利單抗注射液(重組抗PD-1人源化單克隆抗體注射液)或安慰劑聯合化療(卡鉑─依託泊(甘)))在既往未接受過治療的廣泛期小細胞肺癌(ES-SCLC)患者中開展的3期HLX10-005-SCLC301臨牀研究在計劃的期中分析中,經獨立數據監察委員會(IDMC)評估達到總生存期(OS)的主要研究終點。
斯魯利單抗注射液爲公司自主開發的創新型抗PD-1單抗,計劃用於多種實體瘤治療,目前就1項單藥及以其爲核心的8項聯合療法在全球多個國家和地區同步開展臨牀試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.